Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0142)
Name
Dexrazoxane
Synonyms
Dexrazoxane; 24584-09-6; Zinecard; (S)-4,4'-(Propane-1,2-diyl)bis(piperazine-2,6-dione); Cardioxane; ICRF-187; Dextrorazoxane; Dexrazoxanum; Dexrazoxano; Dexrazoxanum [INN-Latin]; Dexrazoxano [INN-Spanish]; ADR-529; Desrazoxane; Eucardion; (+)-(S)-4,4'-Propylenedi-2,6-piperazinedione; 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione; ADR 529; ICRF 187; Razoxane, d-; Razoxane, (s)-; Dexrazone; (+)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane; NSC-169780; CHEBI:50223; Razoxanum [INN-Latin]; Razoxana [INN-Spanish]; dyzoxane; DTXSID3040647; 2,6-Piperazinedione, 4,4'-[(1S)-1-methyl-1,2-ethanediyl]bis-; 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (S)-; NSC 169780; (S)-(+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane; 048L81261F; 4-[(2S)-1-(3,5-dioxopiperazin-1-yl)propan-2-yl]piperazine-2,6-dione; (S)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane; DTXCID1020647; (+)-dexrazoxane; CAS-24584-09-6; 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (+)-; HSDB 7319; (+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane; 2,6-Piperazinedione, 4,4'-propylenedi-, (+)-; SR-01000883995; NSC169780; BRN 5759131; Soluble ICRF (L-isosomer); Dexrazoxane [USAN:INN:BAN]; CCRIS 9394; UNII-048L81261F; NCGC00164737-01; Dexrazoxane- Bio-X; MFCD00866449; DEXRAZOXANE [INN]; DEXRAZOXANE [JAN]; DEXRAZOXANE [HSDB]; DEXRAZOXANE [USAN]; DEXRAZOXANE [VANDF]; CHEMBL1738; DEXRAZOXANE [MART.]; SCHEMBL18400; DEXRAZOXANE [WHO-DD]; MLS006010158; BIDD:GT0068; Dexrazoxane (JAN/USAN/INN); DEXRAZOXANE [EMA EPAR]; 4,4'-(2S)-propane-1,2-diyldipiperazine-2,6-dione; GTPL7330; Dexrazoxane, >=95% (HPLC); (S)-4,4'-(Propane-1,2-diyl)-bis(piperazine-2,6-dione); RAZOXANE (+)-FORM [MI]; AMY39004; HY-B0581; Tox21_112256; 2, 4,4'-propylenedi-, (+)-; BDBM50586360; s5651; AKOS015896392; Tox21_112256_1; (+)-1,5-dioxopiperazin-1-yl)propane; CCG-267131; DB00380; DS-1394; NCGC00263544-01; NCGC00263544-02; BD164365; Dexrazoxane, analytical reference material; NCI60_001367; SMR002529680; (S)-(+)-1,5-dioxopiperazin-1-yl)propane; D4227; D03730; AB01273932-01; AB01273932-02; AB01273932_03; EN300-7356981; 2,4,4'-[(1S)-1-methyl-1,2-ethanediyl]bis-; A817380; Q524995; 2,4,4'-(1-methyl-1,2-ethanediyl)bis-, (S)-; J-015579; J-520219; SR-01000883995-1; SR-01000883995-2; SR-01000883995-5; (S)-4,4'-(propane-1,2-diyl)dipiperazine-2,6-dione; BRD-K07265709-003-01-5; 4,4'-[(2S)-1,2-Propanediyl]di(2,6-piperazinedione); 4,4'-[(1S)-1-Methyl-1,2-ethanediyl]bis-2,6-piperazinedione; 6-hydroxy-4-[(2S)-2-(5-hydroxy-3-oxo-1,2,3,6-tetrahydropyrazin-1-yl)propyl]-2,3,4,5-tetrahydropyrazin-2-one

    Click to Show/Hide
Structure
Formula
C11H16N4O4
IUPAC Name
4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione
Canonical SMILES
CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2
InChI
InChI=1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)/t7-/m0/s1
InChIKey
BMKDZUISNHGIBY-ZETCQYMHSA-N
PubChem CID
71384
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Cardiomyopathy ICD-11: BC43
 Disease Info 
Responsed Regulator High mobility group protein B1 (HMGB1) Driver
 Regulator Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model CHO-S/H9C2 cells Normal Cricetulus griseus CVCL_A0TS
In Vivo Model
Male Wistar rats (250-300 g,n = 230) were purchased from Vitalriver. Ten rats were recruited in each group in the experiment. The rats in the control, DOX, FER-1 + DOX, NEC-1 + DOX, 3-MA + DOX, and Emricasan + DOX groups were used for the overall survival analysis, and those from control and DOX groups were used for detection of the expression of PTGS2 in the indicated organs of rats.

    Click to Show/Hide
Response regulation Dexrazoxane (DXZ) reduces cytotoxicity caused by Doxorubicin (DOX). HMGB1 was induced by DOX but was inhibited by DXZ or FER-1. Overexpression of HMGB1 promoted the ferroptosis and cardiotoxicity induced by DOX in the rats although silencing of HMGB1 showed opposite effects.
References
Ref 1 Protective Effects of Dexazoxane on Rat Ferroptosis in Doxorubicin-Induced Cardiomyopathy Through Regulating HMGB1. Front Cardiovasc Med. 2021 Jul 14;8:685434. doi: 10.3389/fcvm.2021.685434. eCollection 2021.